Put on a Happy Face: A fun, easy and evidence-informed way to use an interactive Cardiovascular Disease Risk Calculator tool in office practice
|
|
|
- Clyde Carson
- 5 years ago
- Views:
Transcription
1 Put on a Happy Face: A fun, easy and evidence-informed way to use an interactive Cardiovascular Disease Risk Calculator tool in office practice Dr. Michael Dillon Klinic Community Health, Winnipeg MB Assistant Professor, Dept. of Family Medicine, U of M
2 Declaration of Conflict of No current involvement with pharmaceutical industry (Boards, consultations, sponsorship). Past academic contribution to Accredited Educational activities that have had some Pharma support Mutual Funds not specifically invested in Pharmaceutical Industry, but in some for-profit medical facilities in the Northern USA Interest No Mutual Fund investment in Big Agriculture
3 Goals of Presentation Same as goals of a good office visit: Start on time, end on time, share some useful content Give some ideas to take home and consider Promote good communication and lifestyle
4 Why do we need to do this better? We as Primary Healthcare Providers are NOT witches and wizards with Magic Solutions for our patients We re NOT all that good at translating ideas of risk and benefit
5 We are not so good with Numeracy We have a hard time explaining risks, benefits, NNT etc.
6 Defence Against the DARK s
7 We dole out Potions Without Really Knowing the Counter-Spells
8 Patient 1: Linda Celebrating her 50th Birthday Had just been to the office for Periodic Health Review: Pap smear done, information to call re ColonCheck FOBT and BreastCheck Agreed to have Lipid Profile and Glucose screen done
9 Linda s Cardiovascular Risk Data Important data: Cigarette Smoker Mother had Heart Attack aged 60 Anishinaabe
10 . BP 130/80 A1c 5.6% T.Chol 7.1 HDL 1.1
11 So doc, what s this mean? Time for the BS ( Best Science )
12 Therapeutics Education Collaboration BS Without the BS James P. McCormack. BSc, BSc (Pharm), PharmD. Faculty of Pharmaceutical Sciences, UBC G Michael Allan, MD, CCFP Professor and Director of EBM, Dept of Family Medicine, U of A Director of Evidence and CPD, Alberta College of Family Physicians
13 So doc, what s this mean? (or just Google BS Medicine CVD Risk Calculator )
14 Age Gender Smoker? Icon Array AKA Bunch o Smileys Diabetes? Blood Pressure T. Cholesterol HDL Family History slider Relative Benefit of actions (*can t really combine on calculator Can print a copy for patient and EMR
15 Patient 1: Linda Next steps: Literal ones!
16 Patient 2: Kostas 48 years old Greek background Smoker, trying to quit with vapes Diabetes diagnosed past two years, struggling with metformin (severe GI upset) Blood Pressure high
17 A1c 9.8 Kostas Total cholesterol 8.6 HDL 0.8 TG 15.2 BP 160/90
18 I don t like taking meds! Note: Crazy high Triglycerides are actually an IMPROVEMENT (fasting specimen this time, usually non-fasting is fine) BUT I HAVE BEEN STICKING TO THE MEDITERRANEAN DIET!
19 So doc, what s this mean? (or just Google BS Medicine CVD Risk Calculator )
20 Patient 2: Kostas Next Steps Try some metformin (if can tolerate!) Nudge the BP meds up a bit Consider a statin in higher dose if tolerated Refer to Clinical Pharmacologist
21 Comprehensive Diabetes Care has same negative burden on quality of life as a mild stroke Perfect"health" Exercise" Diet" Aspirin" CholesterolKlowering"drug" ConvenBonal"BP"control" ConvenBonal"glucose"control" Intensive"BP"control" Mild"stroke" Intensive"glucose"control" Neuropathy" Angina" Comprehensive"diabetes"care" AmputaBon" Blindness" Dialysis" Major"stroke" Death" Quality of Life 1" 0.9" 0.8" 0.7" 0.6" 0.5" 0.4" 0.3" 0.2" 0.1" 0" Diabetes Care 2007;30:
22 Patient 3: Etienne 53 year old man from Sub-Saharan Africa Generally feeling well Lipid screening done as he is on Ritonavir + Protease inhibitor as part of HAART for HIV
23 D:A:D and CV Risk 11 cohorts; 23,437 patients; >94,000 patient years Relative Rate of MI 10 Per 5 years of PI use = 1.61 (95% CI = ) Per 5 years of! age = 1.32 (95% CI = ) Relative Rate 1 PI use Age Male Current Prior DM TC HDL (per 5 yrs) (per 5 yrs) smoker CVD (per mmol) (per mmol) 0.1 CVD: CV disease, D:A:D: Data collection on Adverse events of anti-hiv Drugs, DM: diabetes mellitus, PI: protease inhibitor, TC: total cholesterol The DAD Study Group. N Engl J Med 2007;356:
24 x m No indication Diabetes T. Cholesterol 5.6 HDL 1.4 BP 140/60 HIV +ve (risk slider)
25 So doc, what s this mean? (or just Google BS Medicine CVD Risk Calculator )
26 Patient 3: Etienne Next Steps Using AAC/AHA ASCVD Calculator, he decides to forego a statin for now Continue to be active with his two young kids Continue to eat balanced Mediterranean-style diet CONTINUE HAART
27 How all this helps Shared decision-making and realistic understanding of what risk actually is In conversation with patient there may be more buy-in to whatever intervention patients choose In conversation, we can check off many of our Primary Care Quality Indicators!
28 How all this helps I now order more baseline lipid profiles but less overall (not repeating less than q 5 years, no monitoring on Statins etc.) I am learning how to pronounce empagliflozin and liraglutide I gained Mainpro + Credits by doing a Linking Learning Exercise
29 Unintended and surprising outcomes Stopped Rx ing Atenolol Stopped just automatically adding insulin or sulfonylureas to metformin when the sugars are high I actually am prescribing statins for primary prevention I share my favourite ratatouille recipes with people
30 Thank you/migwitch
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
Welcome to the 19th Annual wow, almost 20 years Drug Therapy Decision Making Course
Welcome to the 19th Annual wow, almost 20 years Drug Therapy Decision Making Course An interactive course on common and new drug therapy issues from an evidence based perspective Education should not be
John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
Lipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
Diabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
Placebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
Hyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
Established Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
Placebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
Primary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins
Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 2 Welcome by Michael Pignone, MD, MPH Hi, my name is Dr.
Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
Prevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
The Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
CVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
Fasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
Finding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
EuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
340B Savings Equals Improved Patient Care
10 th Annual 340B Coalition Winter Conference 340B Savings Equals Improved Patient Care Carol Millage, PharmD Pharmacy Director County of Santa Barbara Public Health February 7, 2014 Statement of Conflicts
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
Controversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
Heart Disease and Diabetes Teaching Module
Heart Disease and Diabetes eaching Module Pre-est 1 Cardiovascular complications will affect of people with diabetes. a. 75% b. 15% c. 99% 2 rue or alse? Chronic high blood sugars can cause arteries to
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
Preventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
Metabolic Syndrome: What s so big about BIG?
Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare
ACC/AHA Guidelines Bulls-eyes and Misses
ACC/AHA Guidelines Bulls-eyes and Misses James Trippi, MD, FACC Diplomate American Board of Clinical Lipidology Complex Cholesterol Center of St. Vincent Health Indianapolis, IN October 18, 2014 Level
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
To fully participate in this session: Please obtain a Framingham Risk Calculator google: My Health Alberta Risk Calculator click: Heart Disease Risk
To fully participate in this session: Please obtain a Framingham Risk Calculator google: My Health Alberta Risk Calculator click: Heart Disease Risk Calculator Worksite Screening and the Unknown Burden
Lipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
Informed Consent, Goals and Targets
Informed Consent, Goals and Targets Kenneth Brummel-Smith, MD Charlotte Edwards Maguire Professor of Geriatrics Florida State University College of Medicine Objectives Understand the nature of true informed
Diabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
Record-Keeping Charts
In this appendix, we have provided some useful charts for you so you can record information that s important to manage your diabetes. Use these charts to keep track of the information not only for yourself,
Atherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
Cardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
Macrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
Management of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
Doctor s Instructions Patient: Mr Abdul Shareef Age: 40. Last Consultation Dr Mitchell 2 weeks ago
Doctor s Instructions Patient: Mr Abdul Shareef Age: 40 Last Consultation Dr Mitchell 2 weeks ago Telephone Triage: Patient just wants a routine blood test as FH of diabetes. Plan: Fasting blood test,
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
Personal Diabetes Passport
Personal Diabetes Passport Contact information: Name: Physician: Diabetes Education Centre: Dietitian: Ophthalmologist: Chiropodist: Type of Diabetes: Type 1 (T1DM) Increased risk for diabetes Type 2(T2DM)
OBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
American Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
Aspirin Resistance and Its Implications in Clinical Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/aspirin-resistance-and-its-implications-in-clinicalpractice/3819/
Diabetes Education Teaching Guide! Heart Disease & Diabetes!
Diabetes Education Teaching Guide! 1 Pre-Test! Question #1 Cardiovascular complications will affect of people with diabetes. A.! 75% B.! 15% C.! 99% 2 Pre-Test! Answer #1 Cardiovascular complications will
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
NEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
Cardiovascular Disease Risk Factors:
Cardiovascular Disease Risk Factors: Risk factors are traits or habits that increase a person's chances of having cardiovascular disease. Some risk factors can be changed. These risk factors are high blood
Type 1 Diabetes & Continuous Glucose Monitoring. Dr Sheila Cook Director of Diabetes & Endocrinology Toowoomba Hospital
Type 1 Diabetes & Continuous Glucose Monitoring Dr Sheila Cook Director of Diabetes & Endocrinology Toowoomba Hospital Let s consider the traditional diabetes clinic The Diabetes Clinic Whenever I check
Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
HIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1
HIV and Common Comorbidities August 17, 2017 Michael MacVeigh, MD & Kristen Meyers, BS, CADC1 Learning Objectives 1) Confidently discuss basics of ARVs and common side effects of these medications 2) Understand
9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure
2013 AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis Robert Gleeson MD Preven5ve Cardiology and Lipid Management Froedtert and The Medical College of Wisconsin Disclosure
Heart Healthy Living Tips
Diabetes and Heart Disease Awareness Healthy Living with Diabetes sm and Heart Healthy Living sm Michigan Newsletter Fall 2011 Heart Healthy Living Tips What do eating healthy, being active, maintaining
Diabetes and Heart Disease Awareness Molina Healthy Living with Diabetes sm and Heart Healthy Living sm
Diabetes and Heart Disease Awareness Molina Healthy Living with Diabetes sm and Heart Healthy Living sm Molina Healthcare of Michigan Summer 2013 Living a Healthy Life with Diabetes Many people avoid the
Cardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
Best Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
Cardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
The Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
What if we could prescribe information that supported patients to understand and own their diabetes?
Briefing Paper Project Information Prescriptions Date /0/05 From Amy Rylance, Head of Healthcare Professional Engagement Page of Introduction: Our Reaching People with Diabetes through Healthcare Professionals
Diabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
Diabetes and Heart Disease
Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research
JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
DIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
Outcomes of diabetes care in England and Wales. A summary of findings from the National Diabetes Audit : Complications and Mortality reports
Outcomes of diabetes care in England and Wales A summary of findings from the National Diabetes Audit 2015 16: Complications and Mortality reports About this report This report is for people with diabetes
Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER
Professional Postgraduate Services Release Date: March 14, 2008 Valid Through: July 14, 2008 Sponsor This educational activity is a component of the National Diabetes Education Initiative (NDEI ), sponsored
Know Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital
Know Your Numbers Your guide to maintaining good health Helpful information from Providence Medical Center and Saint John Hospital If it has been awhile since your last check up and you are searching for
Staying healthy while taking antipsychotic medications
Staying healthy while taking antipsychotic medications For patients and families You are taking antipsychotic medications to help your mental health. Like all medications, they can cause side effects.
Presenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
Pre-diabetes. Dr Neel Basudev. GPSI Lambeth DICT, Diabetes Lead Lambeth CCG
Pre-diabetes Dr Neel Basudev GPSI Lambeth DICT, Diabetes Lead Lambeth CCG The Prevention of Diabetes Where has this come from? Pre-diabetes mellitus (PDM) Term introduced by Tommy G. Thompson (Health &
ABOUT TYPE 2 DIABETES
ABOUT TYPE 2 DIABETES Because the more you know, the better you ll feel. What You ll Find Attitudes and Beliefs Type 2 Diabetes What Is It? Where You ll Find It Page 4-5 This booklet is designed to help
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL